Back to top
more

Assertio (ASRT)

(Delayed Data from NSDQ)

$1.11 USD

1.11
1,030,295

+0.04 (3.74%)

Updated Aug 13, 2024 04:00 PM ET

After-Market: $1.10 -0.01 (-0.90%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Assertio (ASRT) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Assertio (ASRT) closed at $2.23 in the latest trading session, marking a +1.36% move from the prior day.

Assertio (ASRT) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Assertio Holdings' (ASRT) Q1 earnings call, investors will focus on the sales performance of its marketed products.

INmune (INMB) Begins Dosing in Mid-Stage Study With AD Candidate

by Zacks Equity Research

INmune (INMB) doses the first patient in a phase II study with its investigational TNF inhibitor to treat Alzheimer's disease. Stock rises more than 12% post this announcement.

Is Assertio (ASRT) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Assertio (ASRT) and Histogen Inc (HSTO) have performed compared to their sector so far this year.

Actinium (ATNM) Up on Commercialization Deal With Immedica

by Zacks Equity Research

Actinium (ATNM) out-licenses exclusive rights to Iomab-B, an antibody radiation conjugate for facilitating bone-marrow transplant, to Immedica in Europe, the Middle East and North African countries.

Best Value Stocks to Buy for April 13th

by Zacks Equity Research

WFG, GOGL, and ASRT made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 13, 2022.

Aerie (AERI) Expands Market Presence Despite Stiff Competition

by Zacks Equity Research

Aerie (AERI) is progressing well with the development of its ophthalmology pipeline. Its partnership with Santen Pharmaceuticals allows it to expand the presence of its drugs outside the United States.

4 Reasons to Add Novo Nordisk (NVO) Stock to Your Portfolio

by Zacks Equity Research

Novo Nordisk's (NVO) portfolio of marketed drugs are driving year over year growth. The company has one of the broadest diabetes portfolios in the industry.

BioCryst (BCRX) Pauses Enrolment in Key Studies, Stock Down

by Zacks Equity Research

BCX9930 is a BioCryst Pharmaceuticals' (BCRX) oral Factor D inhibitor being evaluated in several studies for the treatment of complement-mediated diseases

JAZZ Inks Deal With Werewolf to Add Oncology Candidate

by Zacks Equity Research

Jazz (JAZZ) signs an agreement to gain rights to Werewolf's engineered cytokine pro-drug candidate WTX-613. The candidate has the potential to treat a wide range of cancer types.

PTC Therapeutics (PTCT) Soars 11.1%: Is Further Upside Left in the Stock?

by Zacks Equity Research

PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks.com featured highlights Assertio Holdings, VAALCO Energy and DLH Holdings

by Zacks Equity Research

Assertio Holdings, VAALCO Energy and DLH Holdings have been highlighted in this Screen of the Week article.

Tirthankar Chakraborty headshot

3 Top Breakout Stocks to Invest In for Solid Returns

by Tirthankar Chakraborty

Assertio Holdings, Inc. (ASRT), VAALCO Energy, Inc. (EGY) and DLH Holdings Corp. (DLHC) have been selected as the breakout stocks for today.

Axsome (AXSM) to Acquire Jazz's Sleep Disorder Drug, Sunosi

by Zacks Equity Research

Axsome (AXSM) inks an agreement with Jazz Pharmaceuticals to acquire the latter's new sleep disorder drug, Sunosi. The transaction is expected to close in the second quarter of 2022.

Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Assertio (ASRT) and Sensus Healthcare, Inc. (SRTS) have performed compared to their sector so far this year.

JAZZ Initiates Zepzelca Basket Study in Advanced Solid Tumors

by Zacks Equity Research

JAZZ enrolls the first patient in a mid-stage study to evaluate its lung cancer drug, Zepzelca, in advanced and difficult-to-treat cancer indications in previously-treated patients.

New Strong Buy Stocks for March 24th

by Zacks Equity Research

ASRT, CPRI, GRIN, OCDX, and KN have been added to the Zacks Rank #1 (Strong Buy) List on March 24, 2022.

Are Investors Undervaluing These Medical Stocks Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

New Strong Buy Stocks for March 15th

by Zacks Equity Research

CPRI, GOGL, EOG, ASRT, and IMO have been added to the Zacks Rank #1 (Strong Buy) List on March 15, 2022.

The Zacks Analyst Blog Highlights USA Truck, TimkenSteel, JAKKS Pacific, United Fire Group, and Assertio Holdings

by Zacks Equity Research

USA Truck, TimkenSteel, JAKKS Pacific, United Fire Group, and Assertio Holdings are included in today's Analyst blog.

Bayer (BAYRY) to Divest a Business Unit to Cinven for $2.6B

by Zacks Equity Research

Bayer (BAYRY) to sell off its Environmental Science Professional business unit to Cinven for $2.6 billion. The company plans to focus on core agricultural businesses.

Allogene's (ALLO) CAR T Therapy Gets Fast Track Designation

by Zacks Equity Research

The FDA grants a Fast Track designation to Allogene's (ALLO) early-stage CAR T therapy candidate, ALLO-316, for treating advanced or metastatic clear cell RCC.

Nalak Das headshot

Top 5 High-Flying Small Hidden Gems Amid Wall Street Mayhem

by Nalak Das

We have narrowed our search to five small-cap stocks that have provided double-digit returns year to date. These are: USAK, TMST, JAKK, UFCS and ASRT.

Bayer (BAYRY) Files for Nubeqa's Label Expansion in US & EU

by Zacks Equity Research

Bayer (BAYRY) submits regulatory applications to the FDA and the EMA, seeking approval for a new indication of Nubeqa for treating metastatic hormone-sensitive prostate cancer.

Is Liquidia Technologies, Inc. (LQDA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Liquidia Technologies, Inc. (LQDA) and Assertio (ASRT) have performed compared to their sector so far this year.